MammoLibrary Mini Moments

How are silent ruptures of silicone gel breast implants found?

What it is

The FDA says most ruptures of silicone gel-filled breast implants are silent. They usually do not change how the implant looks or feels.

How it works

A physical examination alone may not find a silent rupture. The FDA's page says magnetic resonance imaging (MRI) is the most effective method for detecting silent rupture of silicone gel-filled implants, and that ultrasound is an acceptable alternative imaging method for screening for rupture in patients without symptoms. The ultrasound statement was added in the December 2023 update. The page does not state how often to image; patients are directed to their surgeon or health care provider.

Why it matters

The longer an implant is in place, the greater the chance it may rupture, so imaging questions belong in a patient's conversation with their surgeon. Imaging for implant rupture is a different purpose from cancer screening.

What it means to the patient or the client

For patients with silicone gel implants: a rupture may cause no symptoms, so MRI is the most effective way to find one, and ultrasound is an acceptable alternative if you have no symptoms. Ask your surgeon or health care provider how often to be imaged, because the FDA page does not give a schedule.

How does the American Cancer Society say a breast lump is evaluated during pregnancy or breastfeeding?

What it is

The American Cancer Society says breast cancer is found in about 1 in 3,000 pregnant women, and that any lump or breast change should be reported to a healthcare provider at once instead of being assumed to be related to pregnancy.

How it works

Its page says routine screening mammograms are usually delayed during pregnancy, but a diagnostic mammogram is generally considered safe when there is a reason for concern, because the radiation dose is small and is focused on the breasts, and a lead shield is placed over the abdomen. It describes breast ultrasound as safe in pregnancy because it uses no radiation, and it notes that ultrasound can show whether a mass is solid or fluid filled. It says breast MRI is not recommended during pregnancy because the gadolinium contrast has been linked with fetal damage in the first trimester. It also notes that pregnancy and breastfeeding make breast tissue denser, which can make an early cancer harder to see on a mammogram. Core needle biopsy is described as low risk to the fetus.

Why it matters

A lump in a pregnant or breastfeeding patient needs prompt evaluation, and the imaging order differs from routine screening.

What it means to the patient or the client

For patients: report any new lump to your healthcare provider right away, even if you think it is related to pregnancy or nursing. For the client: make sure scheduling and technologist staff know to route a symptomatic pregnant or breastfeeding patient to a diagnostic pathway and not to a screening slot. The imaging choice is the radiologist's and referring provider's decision.

What does the American Cancer Society say about mammography for transgender and gender nonconforming people?

What it is

The American Cancer Society's guide for healthcare professionals says people with mature or developed breast tissue should have a mammogram per ACS guidelines. It gives two examples: transgender men who have not had top surgery, and people who developed breast tissue from hormone therapy, such as transgender women or others who have taken estrogen.

How it works

The guide also lists a family history of breast cancer or cancer syndromes such as BRCA as an assessment consideration, and chemoprevention to help reduce risk as an intervention to consider. It says transgender and gender nonconforming people are less likely to be offered appropriate screening tests, are less likely to be screened for breast, cervical, and colorectal cancers, and are more likely to be diagnosed at a later stage than cisgender people. It also says many delay or avoid care out of fear of discrimination. The guide does not compare ACS guidance with other societies' guidance, so a statement about whether societies agree or conflict would need other sources.

Why it matters

Screening depends on breast tissue and risk factors, and an inclusive process helps patients get screened.

What it means to the patient or the client

For the client: confirm that your scheduling, registration, and reports can handle a patient whose recorded sex does not match their anatomy, and that staff are trained to be respectful. The mammography facility's MQSA obligations are the same for every patient.

What does the American Cancer Society say about supplemental imaging for women with dense breasts?

What it is

The American Cancer Society says that at this time experts do not agree what other tests, if any, should be done in addition to mammograms in women with dense breasts, and it advises talking with a healthcare provider about whether to consider any of them.

How it works

Its page says some studies suggest 3D mammography may be particularly helpful in women with dense breasts, and that ultrasound and MRI can find some cancers that mammograms cannot see but can also show more findings that are not cancer, which can lead to more tests and unnecessary biopsies. It adds that insurance may not cover the cost of an ultrasound or MRI. The page says any woman already in a high risk group should have an MRI along with her yearly mammogram. The page, last revised September 9, 2024, does not mention molecular breast imaging, so it does not rank that test against MRI.

Why it matters

There is no single recommended add-on test for everyone with dense breasts, so the choice is individual.

What it means to the patient or the client

For patients: ask your healthcare provider whether any added imaging makes sense for you, and check coverage with your insurer first. For the client: keep patient materials neutral about supplemental imaging and refer patients to their healthcare provider.

What mammography follow-up does the American Cancer Society describe after breast surgery?

What it is

After breast-conserving surgery, the American Cancer Society says experts recommend a mammogram of the treated breast 6 to 12 months after treatment ends, and typically at least yearly after that, with routine screening continuing on the other breast.

How it works

After a mastectomy on one side, the ACS page says routine screening mammograms are not needed on that side but are still needed on the remaining breast, and notes that for nipple-sparing mastectomy some doctors may recommend follow-up mammograms because breast tissue can remain. After removal of both breasts, mammograms should no longer be needed. After reconstruction following a simple, modified radical, or radical mastectomy, routine mammograms of the affected breast are not needed, but a concern on physical exam can lead to a diagnostic mammogram and breast ultrasound, with breast MRI sometimes used to clarify. The page was last revised July 23, 2026. It does not address imaging for other situations such as high-risk surveillance.

Why it matters

The right imaging depends on the type of surgery, so patients and schedulers need the surgery type on record.

What it means to the patient or the client

For patients: ask your care team which breasts still need yearly mammograms. For the client: record the type of surgery for each patient so the screening schedule and any reminder reflect it, and route a concern after reconstruction to a diagnostic exam.

How does Medicare cover screening, baseline, and diagnostic mammograms?

What it is

According to Medicare.gov, Medicare covers a screening mammogram once every 12 months for a woman 40 or older, and a baseline mammogram once in a lifetime for a woman aged 35 to 39. The patient pays nothing for either test if the provider accepts assignment.

How it works

For a diagnostic mammogram, the page says the patient pays 20 percent of the Medicare-approved amount after meeting the Part B deductible, and that a diagnostic mammogram is covered more often than once a year if medically necessary. The page does not mention 3D mammography and shows no date, so a facility should check coverage details and any conversion of a screening exam to a diagnostic exam in the CMS claims manual or with its Medicare contractor. MQSA does not address coverage or reimbursement; the CMS regulations govern it.

Why it matters

Whether an exam is billed as screening or diagnostic changes what the patient pays.

What it means to the patient or the client

For patients: ask your provider whether your exam is screening or diagnostic, because the cost differs. For the client: train staff to explain the difference and to check the CMS billing rules before an exam changes type during a visit.

What does Medicare say when a screening mammogram turns into a diagnostic mammogram on the same day?

What it is

A Medicare coverage policy from one Medicare contractor, CGS Administrators for Kentucky and Ohio (policy L33950, revised December 4, 2025), says the interpreting radiologist may order the additional views without a new order from the treating physician and may bill for both the screening and the diagnostic mammogram.

How it works

The same policy says the radiologist who adds views must refer to the treating physician or qualified practitioner for that person's National Provider Identifier and report the patient's condition back to the treating provider. If there is no treating or referring physician, the radiologist reports the results directly to the patient. The cost of the additional views is included in the fee for the diagnostic service, and a note in the radiologist's report satisfies the order requirement. Other Medicare contractors publish their own policies, so a facility should check the one that covers it. MQSA does not address payment.

Why it matters

The conversion is allowed without a new order, but the report note, the referral, and the notification back to the treating provider still have to happen.

What it means to the patient or the client

For the client: make sure your report template records the conversion and the reason, and that your process reports the result to the treating provider or, if none, to the patient. Check your own Medicare contractor's policy, because this one covers only Kentucky and Ohio.

What limits does a Medicare contractor policy put on screening mammography?

What it is

The CGS Administrators policy (L33950, Kentucky and Ohio, revised December 4, 2025) says Medicare pays for a screening mammogram only when at least 11 months have passed after the month of the last screening mammogram.

How it works

The policy also says the service must be at least two views of each breast, cranio-caudal and medio-lateral oblique, and that payment cannot be made for screening mammography for a woman under 35. It says no physician referral is needed for a screening mammogram, that Medicare reimburses only FDA-certified mammography centers, and that screening mammography cannot be performed by a portable x-ray supplier. It also limits releasing screening films to physicians who are not approved under the facility's certification number, with the example of a patient who asks for a transfer for a second opinion. Medicare.gov describes the same annual coverage without the contractor level details.

Why it matters

A screening exam booked too early, or without both views, may not be paid.

What it means to the patient or the client

For patients: ask your facility whether your last screening was long enough ago to be covered. For the client: build the 11 month check into scheduling, and check your own contractor's policy for any differences.

When does a Medicare contractor policy cover breast ultrasound and breast MRI?

What it is

The CGS Administrators policy (L33950, revised December 4, 2025) lists conditions for breast sonography, including guiding interventional procedures, implant problems, initial evaluation of palpable masses in women under 30, evaluation of lactating or pregnant women, palpable abnormalities, and telling cysts from solid lesions.

How it works

It says breast ultrasound should not be routinely used along with diagnostic mammography, though it may be indicated for some ambiguous masses or asymmetries, and that ultrasound may be done without a prior diagnostic mammogram if the treating physician orders it. For breast MRI the policy says use should be very selective: inconclusive diagnosis after a standard work-up, post-operative scar versus tumor, positive axillary nodes with no known primary, implant rupture, or extent of disease in a known malignancy before treatment. Ductography is described as useful for abnormal nipple discharge. The policy has no specific coverage statement for automated breast ultrasound or tomosynthesis. It is one contractor's policy and applies to Kentucky and Ohio.

Why it matters

Coverage differs by modality, so the order and the indication need to match what the payer lists.

What it means to the patient or the client

For patients: ask your provider and your plan whether an ultrasound or MRI is covered for your situation. For the client: keep the indication on every order for these exams, and look up your own contractor's policy before you promise coverage.

When does a Medicare contractor policy say diagnostic mammography is indicated, and who must supervise it?

What it is

The CGS Administrators policy (L33950, revised December 4, 2025) lists indications for diagnostic mammography: signs or symptoms suggestive of malignancy such as a mass, some spontaneous nipple discharge, skin changes, unilateral breast pain, or unilateral axillary nodes, and radiographic abnormalities found on screening mammography.

How it works

Other listed indications include metastatic disease of undetermined origin where the breast is the suspected source, axillary lymphadenopathy of undetermined cause, short interval follow-up at six month intervals for two years for unresolved concerns, a personal history of breast cancer, and benign biopsy-proven breast disease. The policy says diagnostic mammography must be done under the direct supervision of an interpreting physician qualified in mammography, who must be present and immediately available. For digital mammography, direct supervision may also be met by telemammography, but the radiologist must still be available to take the history, examine the patient, and discuss results within an acceptable time.

Why it matters

The payer's list defines when a diagnostic exam is considered medically necessary, and the supervision rule ties to the interpreting physician qualifications MQSA requires.

What it means to the patient or the client

For the client: check that your diagnostic exam orders carry one of these indications, and that your supervision and telemammography arrangements meet the policy.

Which breast imaging services need an order from the treating provider under a Medicare contractor policy?

What it is

The CGS Administrators policy (L33950, revised December 4, 2025) says a screening mammogram needs no referral, but a treating provider's referral is required for diagnostic mammography, and a treating provider's order is required for breast ultrasound, breast MRI, and ductography.

How it works

For diagnostic mammography the exception is the same day case, where the radiologist adds views after a screening exam finds an abnormality; a note in the radiologist's report fulfills the requirement. The policy says the order requirement does not apply to hospital based radiologists for inpatient or outpatient diagnostic mammography or breast ultrasound. It cites the Medicare rule that diagnostic tests must be ordered by the treating physician or practitioner who uses the results (42 CFR 410.32), and says the referral should name the diagnosis prompting the diagnostic mammogram.

Why it matters

A missing order is a payment problem and can mean the exam was not medically necessary in the payer's eyes.

What it means to the patient or the client

For the client: have scheduling confirm the order before the diagnostic exam, ultrasound, MRI, or ductography, and record the diagnosis the order gives. This is one contractor's policy, so confirm with yours.

What is MammoLibrary?

What it is

MammoLibrary is the reference and source-document archive of the Mammologix Knowledge Hub. It gives breast imaging professionals direct access to the underlying documents that shape mammography regulation, compliance, quality, and practice [1].

How it works

The collection is searchable and browser-based, and it brings together federal regulations, Federal Register notices, FDA guidance, manuals, white papers, research materials, checklists, and quick-reference documents. Documents can be searched by title, topic, or content and reviewed within the website. Contextual descriptions explain why a source matters and who may find it useful [1].

Why it matters

Users do not have to search across numerous government websites, archives, publications, and document repositories when researching a breast imaging question. The descriptions also show where a document fits within mammography practice, not only where to find it.

What is the Mammologix.com newsfeed?

What it is

The Mammologix.com newsfeed is a scrolling Breast Imaging News ticker at the top of the Resources page at mammologix.com/resources. It shows breast imaging and breast cancer news from around the country [1].

How it works

Mammologix gathers the news automatically from hundreds of sites and runs the headlines in the ticker. The ticker is public and needs no sign-in [1].

Why it matters

An administrator, navigator, or patient can see current breast imaging and breast cancer news in one place without checking many sites. A feed reader such as Feedly can help a person who wants to build a personal feed alongside it.

What is MammoToolbox?

What it is

MammoToolbox is the interactive working area of the Mammologix Knowledge Hub. It turns breast imaging information into calculators, analytical tools, assessment instruments, compliance resources, policy templates, and practice aids built around the operational needs of breast imaging programs [1].

How it works

A user enters information, explores data, evaluates performance, and leaves with something useful. Users can calculate and evaluate measures such as Abnormal Interpretation Rate and positive predictive values, explore national MQSA statistics, model the downstream financial impact of a mammography program, assess patient education materials for understandability and actionability, and access customizable policy and procedure resources [1].

Why it matters

Administrators, radiologists, navigators, compliance professionals, and operational leaders can calculate, compare, evaluate, plan, or solve a problem instead of only reading about it. Both clients and nonclients can use it.

Does MQSA address insurance coverage for mammography or supplemental imaging?

What it is

No. The FDA said insurance coverage and reimbursement are outside the scope of its authority under the MQSA, and it declined recommendations to address them. The explanation comes from the FDA's responses to public comments in the preamble of the 2023 final rule.

How it works

Commenters asked the FDA to require coverage of all breast imaging, additional reimbursement for rural facilities, and statements about coverage in patient communications. The FDA declined, saying it considers these recommendations outside its authority, and that including references to insurance coverage in the lay summary may distract from the breast density notification. The FDA recommended that patients check with their insurance company about coverage before undergoing a mammogram.

Why it matters

The density notification is not a coverage notice, and coverage rules come from payers and state and federal law.

What it means to the patient or the client

For patients: ask your insurer what is covered before your exam, especially for supplemental imaging. For the client: keep coverage information out of the required density statement and use separate materials for it.

Is thermography an alternative to mammography?

What it is

No, according to the FDA. In the preamble of the 2023 final rule the FDA said breast thermography is outside the scope of the MQSA and that it has issued a Safety Communication and a Consumer Update warning that thermography is not an effective alternative to mammography.

How it works

The FDA said there is no valid scientific data to demonstrate that thermography devices, on their own or with another diagnostic test, are an effective screening tool for any medical condition, including the early detection of breast cancer. It also said that people who choose thermography instead of mammography may miss the chance to detect breast cancer at its earliest and most treatable stages. The FDA declined a request to approve thermography and ultrasound together as an alternative to mammography.

Why it matters

Replacing a mammogram with thermography can delay detection.

What it means to the patient or the client

For patients: if you are offered thermography instead of a mammogram, talk with your healthcare provider about it, because the FDA says it is not an effective substitute. For the client: do not present thermography as a replacement for mammography in patient materials.

Is computed tomography of the breast regulated under MQSA, and does the FDA review clinical images?

What it is

No to breast CT. The FDA's Small Entity Compliance Guide says computed tomography of the breast is not regulated under the MQSA regulations, citing 21 CFR 900.2(aa)(3).

How it works

The guide also says the regulations generally do not apply to radiography of the breast performed during invasive interventions for localization or biopsy, or with an investigational mammography device in a study under the FDA's investigational device exemption rules. It says the MQSA and its regulations do not contain clinical practice guidelines, such as the age range or time interval for screening, and that interpreting the images is the responsibility of the qualified interpreting physician. The FDA does not typically review clinical images for quality, since that is generally done by the accreditation bodies.

Why it matters

The scope of MQSA is mammography, so other breast imaging follows other rules and accreditation.

What it means to the patient or the client

For the client: do not assume your MQSA certificate or inspection covers breast CT, ultrasound, or MRI, and ask the relevant accreditor about those services.

What does the American Cancer Society recommend for screening mammography at average risk?

What it is

The American Cancer Society recommends screening mammography on a schedule that depends on age for women at average risk of breast cancer. This is a professional society recommendation, not a federal regulation.

How it works

Women ages 40 to 44 have the option to start screening with a mammogram every year. Women 45 to 54 should get mammograms every year. Women 55 and older can switch to a mammogram every other year, or continue yearly mammograms. The ACS does not recommend clinical breast exams for breast cancer screening in average risk women at any age.

Why it matters

Different groups, such as the U.S. Preventive Services Task Force, recommend different starting ages and intervals, so patient materials should say which recommendation they follow. The page was last revised July 23, 2026.

What it means to the patient or the client

For patients: the ACS schedule depends on your age, and other groups recommend different starting ages and intervals, so ask your healthcare provider which one fits you. For the client: say in patient materials which recommendation you follow.

What does the American Cancer Society recommend for women at higher risk, including breast MRI?

What it is

The American Cancer Society recommends a breast MRI and a mammogram every year for women at high risk of breast cancer, typically starting at age 30. This is a professional society recommendation.

How it works

The ACS places in the high risk group women with a lifetime risk of about 20% to 25% or greater according to risk assessment tools that rely mainly on family history, women with a known BRCA1 or BRCA2 mutation, untested first degree relatives of carriers, women who had chest radiation therapy before age 30, and women with Li-Fraumeni, Cowden, or Bannayan-Riley-Ruvalcaba syndrome. It recommends against MRI screening for women whose lifetime risk is less than 15%, and says evidence is insufficient for women at 15% to 20%.

Why it matters

Risk assessment is what places a woman in the high risk group, so a facility that offers supplemental MRI needs a documented way to assess lifetime risk. Other groups, such as the NCCN, publish their own recommendations.

What it means to the patient or the client

For patients: if you have a strong family history, a known BRCA mutation, or had chest radiation before age 30, ask your healthcare provider whether you are in the higher risk group. For the client: offering supplemental MRI needs a documented way to assess lifetime risk.